Company Financials

Carisma Therapeutics, Inc. Financials

United States dollar

business Carisma Therapeutics, Inc. Company Profile

Main Stock Listing

NASDAQ: CARM

Market Capitalization None as of None

Market Cap History

Valuations Metrics as of May. 5, 2024

Trailing PE -0.63
Forward PE -1.26
Price to Sales TTM $4.51
Price to Book MRQ $2.48
Enterprise to Revenue -0.48
Enterprise to EBITDA 0.08

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends 2023-12-31
Most Recent Quarter 2023-12-31
Profit Margin 0.00%
Operating Margin -602.71%
Return on Assets TTM -68.59%
Return on Equity TTM -327.45%

Income Statement

Revenue TTM $14,919,000
Revenue per Share TTM $0.45
Quarterly Revenue Growth 15.00%
Gross Profit TTM $0
EBITDA $-85,894,000
Net Income to Common TTM $-86,879,000
Diluted EPS TTM $-2.59
Quarterly Earnings Growth YoY %

Balance Sheet

Total Cash MRQ $77,605,000
Total Cash per Share MRQ $1.87
Total Debt MRQ $
Total Debt to Equity MRQ 11.77
Current Ratio MRQ 5.06
Book Value per Share MRQ $0.65

Cash Flow

Operating Cash Flow TTM $-81,177,000
Levered Free Cash Flow TTM $-51,520,876

CARM Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding 41,542,500
Float Shares 22,506,083
Avg 10 Volume 108,999
Avg 30 Volume None
Shares Short 1,648,680
Short Ratio 8.32
Short % of Shares 5.31%
% Held by Insiders 28.68%
% Held by Institutions 40.81%

Stock Price Summary

Beta
Fifty Two Week Low $1.53
Fifty Two Week High $9.77
Fifty Two Week Change -274.69%
Day 50 MA $2.14
Day 200 MA $3.38

Dividends and Splits

Forward Annual Dividend Rate $1.45
Forward Annual Dividend Yield 89.25%
Trailing Annual Dividend Rate $0.00
Trailing Annual Dividend Yield 0.00%
Payout Ratio 0.00%
Dividend Date 2023-03-08
Ex Dividend Date 2023-03-08
Last Split Factor
Last Split Date 2023-03-08